MABXIENCE INAUGURATES NEW MONOCLONAL ANTIBODY BIOSIMILAR PLANT IN ARGENTINA
[caption id="attachment_9277" align="aligncenter" width="1079"]
Press Release[/caption]
The laboratory mAbxience, which is part of Insud Pharma, has inaugurated a new biosimilar monoclonal antibody plant in Gar?n, Buenos Aires (Argentina). These drugs are used in the treatment of oncological and autoimmune diseases such as rheumatoid arthritis.
With this new plant, the company now has three biosimilar plants, two in Argentina and one in Spain (Le?n).
The project involved a 40 million dollar investment and represents a significant milestone in the Latin American biopharmaceutical industry. Thanks to the commissioning of the new plant, mAbxience has doubled its production capacity, and will be equipped to meet Argentinian and international demand for the next 10 years. The company exports biosimilars from Argentina to Central America, South America, Africa, Asia and the Middle East.
The entry of biosimilars into the market has cut healthcare expenditure by 40%, supporting the sustainability of healthcare systems and allowing for increased patient access to treatment for complex diseases. ?mAbxience has saved in Argentina the equivalent of 400 million dollars since it started marketing biosimilar monoclonal antibodies, and its presence in the market has forced the country?s only seller of imported products to lower its prices,? said Hugo Sigman, founder of the Insud Group.
The plant currently has 162 employees. Its commissioning allowed for the immediate creation of 50 new jobs and it is expected to generate another 50 positions over the coming years. mAbxience?s team of biotechnologists, biochemists, biologists, pharmacists and technicians undertake all operations in accordance with the strictest global Good Manufacturing Practices (GMPs).
Since the company?s inception, more than 35,000 patients have been treated with these drugs in Latin America, all of whom have been monitored under a comprehensive pharmacovigilance programme. The additional output generated at the new plant will allow more patients to access treatment in Argentina and worldwide. In Argentina, marketing of Rituximab and Bevacizumab is undertaken by the laboratory ELEA.
About mAbxience
mAbxience, part of Insud Pharma, is a global biotechnology company with ten years? experience in biosimilar monoclonal antibody research, development, manufacturing and marketing. The company strives to afford broader patient access to quality treatments for conditions that require high-cost medications, contributing to the sustainability of healthcare systems.
mAbxience is part of Insud, the business group founded by Drs Hugo Sigman and Silvia Gold. The group has over 40 years? experience in the pharmaceutical sector and employs over 6,000 professionals worldwide.
Press Release[/caption]
The laboratory mAbxience, which is part of Insud Pharma, has inaugurated a new biosimilar monoclonal antibody plant in Gar?n, Buenos Aires (Argentina). These drugs are used in the treatment of oncological and autoimmune diseases such as rheumatoid arthritis.
With this new plant, the company now has three biosimilar plants, two in Argentina and one in Spain (Le?n).
The project involved a 40 million dollar investment and represents a significant milestone in the Latin American biopharmaceutical industry. Thanks to the commissioning of the new plant, mAbxience has doubled its production capacity, and will be equipped to meet Argentinian and international demand for the next 10 years. The company exports biosimilars from Argentina to Central America, South America, Africa, Asia and the Middle East.
The entry of biosimilars into the market has cut healthcare expenditure by 40%, supporting the sustainability of healthcare systems and allowing for increased patient access to treatment for complex diseases. ?mAbxience has saved in Argentina the equivalent of 400 million dollars since it started marketing biosimilar monoclonal antibodies, and its presence in the market has forced the country?s only seller of imported products to lower its prices,? said Hugo Sigman, founder of the Insud Group.
The plant currently has 162 employees. Its commissioning allowed for the immediate creation of 50 new jobs and it is expected to generate another 50 positions over the coming years. mAbxience?s team of biotechnologists, biochemists, biologists, pharmacists and technicians undertake all operations in accordance with the strictest global Good Manufacturing Practices (GMPs).
Since the company?s inception, more than 35,000 patients have been treated with these drugs in Latin America, all of whom have been monitored under a comprehensive pharmacovigilance programme. The additional output generated at the new plant will allow more patients to access treatment in Argentina and worldwide. In Argentina, marketing of Rituximab and Bevacizumab is undertaken by the laboratory ELEA.
About mAbxience
mAbxience, part of Insud Pharma, is a global biotechnology company with ten years? experience in biosimilar monoclonal antibody research, development, manufacturing and marketing. The company strives to afford broader patient access to quality treatments for conditions that require high-cost medications, contributing to the sustainability of healthcare systems.
mAbxience is part of Insud, the business group founded by Drs Hugo Sigman and Silvia Gold. The group has over 40 years? experience in the pharmaceutical sector and employs over 6,000 professionals worldwide.
